Rheumatology

JAK inhibitors for RA: Is VTE risk overblown?

EXPERT ANALYSIS FROM RWCS 2018 MAUI, HAWAII (FRONTLINE MEDICAL NEWS) – Rheumatologists, regulatory agencies, ...

‘Real-world’ study finds treat-to-target benefits out to 5 years

FROM CLINICAL RHEUMATOLOGY A treat-to-target (T2T) strategy in daily clinical practice for patients with ...

Treat to target in RA: Finding the right path forward

It makes intuitive sense: Setting a specific goal and working quickly and systematically toward ...

CV risk factors go undiagnosed, untreated in many psoriatic patients

FROM JOURNAL OF RHEUMATOLOGY A significant proportion of patients with psoriasis and psoriatic arthritis ...

Menopause accelerates RA functional decline

FROM RHEUMATOLOGY Rheumatoid arthritis gets worse after menopause, likely because of lower hormone levels, ...

Turmeric-, frankincense-derived supplement shows OA benefit

FROM BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE A combination of curcumin extracted from the turmeric ...

Checkpoint inhibitors look safe in rheumatology patients

FROM ARTHRITIS AND RHEUMATOLOGY People with rheumatologic diseases and cancer appear to be at ...

Low-dose rituximab cuts infection risk

FROM RHEUMATOLOGY Treating rheumatoid arthritis patients with lower doses of rituximab for long-term maintenance ...

Ultrasound could have utility in predicting which RA patients stay in remission

FROM JOURNAL OF RHEUMATOLOGY Synovitis detected by ultrasound in patients with rheumatoid arthritis (RA) ...

Arthritis treatment costs per person held steady from 2008 to 2014

FROM JOURNAL OF RHEUMATOLOGY The annual direct health care expenditures per person with arthritis ...